Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
== Pre-Proto-Hassuna == More recently, the concept of a very early 'Pre-Proto-Hassuna' pottery tradition has been introduced by some scholars. This has been prompted by more recent discoveries of still earlier pottery traditions. Pre-Proto-Hassuna refers to the Late Neolithic period in Upper Mesopotamia when the ceramic containers were just being introduced. The pottery vessels were still very few in number in these early settlements. At that time, the main emphasis was on the pottery with a mineral temper, as opposed to the plant-tempered pottery which came to predominate later. The time frame for this period was about 7000-6700 BC, and at this time stone vessels and White Ware were still being used in addition to pottery. Because of the narrow local emphasis in many pottery studies as of now, these earliest pottery traditions may be known in literature as:
In the case of active targeting, quantum dots are functionalized with tumor-specific binding sites to selectively bind to tumor cells. Passive targeting uses the enhanced permeation and retention of tumor cells for the delivery of quantum dot probes. Fast-growing tumor cells typically have more permeable membranes than healthy cells, allowing the leakage of small nanoparticles into the cell body. Moreover, tumor cells lack an effective lymphatic drainage system, which leads to subsequent nanoparticle accumulation. Quantum dot probes exhibit in vivo toxicity. For example, CdSe nanocrystals are highly toxic to cultured cells under UV illumination, because the particles dissolve, in a process known as photolysis, to release toxic cadmium ions into the culture medium. In the absence of UV irradiation, however, quantum dots with a stable polymer coating have been found to be essentially nontoxic. Hydrogel encapsulation of quantum dots allows for quantum dots to be introduced into a stable aqueous solution, reducing the possibility of cadmium leakage. Then again, only little is known about the excretion process of quantum dots from living organisms. In another potential application, quantum dots are being investigated as the inorganic fluorophore for intra-operative detection of tumors using fluorescence spectroscopy. Delivery of undamaged quantum dots to the cell cytoplasm has been a challenge with existing techniques.
=== Sightings === The investigation into the child's disappearance was slow to commence and soon slowed down further due to the lack of credible leads. Nevertheless, the case had sparked public interest to a degree that sightings of Mendonça were numerous over the years since his disappearance. A prostitute, Alcina Dias, confirmed that Afonso had taken Mendonça to see her on the day he disappeared. Dias allegedly drove up to see her in his car and asked her if she was working. When she assented, he offered to pay her to have sex with Mendonça. Alcina Dias said that Mendonça was extremely nervous and crying by the time he exited the vehicle, reportedly saying that Afonso had forced him to meet her. Alcina Dias added that she tried to calm the boy down and asked him if his mother knew he was there, to which the boy replied no. Mendonça then allegedly drove off in Afonso's vehicle. Alcina Dias allegedly tried to give her deposition to the authorities, but could never identify Dias by name. In 2011, she finally identified him in a court of law. In April 1998, the political commentator Nuno Rogeiro traveled to Disneyland Paris with his family. During the trip, the Rogeiro family snapped several photographs whilst on a ride; one of these photos depicts a boy sitting behind the family who reportedly looks remarkably like Mendonça. Sitting next to the boy was a man in his 40s wearing a red jacket. The Portuguese police did confiscate the photographs for further analysis, but no further progress was made regarding this sighting.
=== Middle Eastern culture === The scorpion is a culturally significant animal, appearing as a motif in art, especially in Islamic art in the Middle East. A scorpion motif is often woven into Turkish kilim flat-weave carpets, for protection from their sting. The scorpion is perceived both as an embodiment of evil and a protective force such as a dervish's powers to combat evil. In another context, the scorpion portrays human sexuality. Scorpions are used in folk medicine in South Asia, especially in antidotes for scorpion stings. One of the earliest occurrences of the scorpion in culture is its inclusion, as Scorpio, in the 12 signs of the Zodiac by Babylonian astronomers during the Chaldean period. In ancient Egypt, the goddess Serket was often depicted as a scorpion, one of several goddesses who protected the Pharaoh. Alongside serpents, scorpions are used to symbolize evil in the New Testament. In Luke 10:19 it is written, "Behold, I give unto you power to tread on serpents and scorpions, and over all the power of the enemy: and nothing shall by any means hurt you." Here, scorpions and serpents symbolize evil. Revelation 9:3 speaks of "the power of the scorpions of the earth."
== Selected articles == Peerschke EI, Zucker MB. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood. 1981;57:663–70. Peerschke EI, Grant RA, Zucker MB. Decreased association of 45calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation. Br J Haematol. 1980;46:247–56. Peerschke EI. Induction of human platelet fibrinogen receptors by epinephrine in the absence of released ADP. Blood. 1982;60:71–7. Peerschke EI. Evidence for interaction between platelet fibrinogen receptors. Blood. 1982;60:973–8. Peerschke EI, Wainer JA. Examination of irreversible platelet-fibrinogen interactions. Am J Physiol. 1985;248:C466–72. Peerschke EI. Decreased accessibility of platelet-bound fibrinogen to antibody and enzyme probes. Blood. 1989;74:682–9. Peerschke EI, Francis CW, Marder VJ. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood. 1986;67:385–90. Peerschke EI, Galanakis DK. The synthetic RGDS peptide inhibits the binding of fibrinogen lacking intact alpha chain carboxyterminal sequences to human blood platelets. Blood. 1987;69:950–2. Peerschke EI. Bound fibrinogen distribution on stimulated platelets. Examination by confocal scanning laser microscopy. Am J Pathol. 1995;147:678–87. Peerschke EI. Maintenance of GPIIb-IIIa avidity supporting "irreversible" fibrinogen binding is energy-dependent. J Lab Clin Med. 1999;134:398–404. Peerschke EI. Reversible and irreversible binding of fibrinogen to platelets. Platelets. 1997;8:311–7.
Sources: en.wikipedia.org
=== Drug target === POMC is a pharmacological target for obesity treatment. The combination drug naltrexone/bupropion acts on hypothalamic POMC neurons to reduce appetite and food intake. In rare cases of POMC deficiency, treatment with setmelanotide, a selective melanocortin-4 receptor agonist, has been effective. Two individuals with confirmed POMC deficiency showed clinical improvement following this therapy.
== Environmental concerns == A large Swedish study shows that it is broken down in wastewater plants and does not release into waterways. A Danish study shows that it biodegrades quickly, but that a risk of continuous leaching from boat paint may cause environmental toxicity.
== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1WXE, PDB: 1WXF, PDB: 1WXG, PDB: 1WXH, PDB: 1WXI, PDB: 1XNG, PDB: 1XNH, PDB: 2E18, PDB: 2PZ8, PDB: 2PZA, and PDB: 2PZB.
== First ministry == The first Bjelke-Petersen ministry was sworn in by Governor Alan Mansfield on 8 August 1968, and served until the reconstitution of the Ministry on 29 May 1969. It was almost unchanged from the Pizzey Ministry and Chalk Ministry. Max Hodges was appointed to fill the cabinet vacancy caused by Jack Pizzey's death, and the roles vacated by Bjelke-Petersen on becoming Premier.
Solorinic acid is an anthraquinone pigment found in the leafy lichen Solorina crocea. It is responsible for the strong orange colour of the medulla and the underside of the thallus in that species. In its purified crystalline form, it exists as orange-red crystals with a melting point of 201 °C (394 °F). The structure of solorinic acid, 2-n-hexanoyl-1,3,8-trihydroxy-6-methoxy-anthraquinone, was proposed by Koller and Russ in 1937, and verified by chemical synthesis in 1966. Norsolorinic acid, (C20H18O7, 2-hexanoyl-1,3,6,8-tetrahydroxyanthraquinone), is a closely related compound also found in Solorina crocea. Solorinic acid was used as the internal standard in the establishment of a standardized method for the identification of lichen products using high-performance liquid chromatography. This is because it is quite a hydrophobic compound, and consequently will elute more slowly than most lichen products, making possible the identification of lichen extracts containing chlorinated xanthones or long chain depsides. Although usually associated with Solorina crocea, solorinic acid was reported as a lichen product from the crustose, rock-dwelling lichen Placolecis kunmingensis, described as a species new to science in 2019.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.